Xeris Biopharma Holdings, Inc. (XERS) Stock Price & Analysis
Xeris Biopharma Holdings, Inc. (XERS) rose 4.17% to USD 6.5 as of June 10, 2026 at 09:11 UTC, according to Nexqual real-time market data.
XERS last closed at USD 6.24; the session ranged USD 6.25–6.54 on volume of 1,643,721 shares. Market capitalization is $1.12B, with a 52-week range of USD 4.3–10.08 (NMS). Source: Nexqual, June 10, 2026 at 09:11 UTC.
Key Statistics (as of June 10, 2026 at 09:11 UTC)
| Price | USD 6.5 |
|---|---|
| Change | ▲ 4.17% (up) |
| Previous Close | USD 6.24 |
| Open | USD 6.25 |
| Day Range | USD 6.25 – 6.54 |
| 52-Week Range | USD 4.3 – 10.08 |
| Volume | 1,643,721 shares |
| Market Cap | $1.12B |
| Exchange | NMS |
Technical Analysis (XERS)
Nexqual's technical model rates XERS "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 09:11 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.3 (neutral) |
| vs SMA50 | Above (USD 6.12) |
| MACD | -0.01 (negative) |
Analyst Ratings (XERS)
Wall Street analysts rate XERS "None" based on 7 analysts, with a mean price target of USD 11.29 (range USD 8–18), per Nexqual as of June 10, 2026 at 09:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 11.29 |
| High Target | USD 18 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (XERS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0 |
| Revenue Estimate | $90.86M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.01 vs est -0 ▲ beat |
| 2025-12-31 | USD 0.06 vs est 0.05 ▲ beat |
| 2025-09-30 | USD 0 vs est 0.01 ▼ miss |
| 2025-06-30 | USD -0.01 vs est -0.03 ▲ beat |
Source: Nexqual, June 10, 2026 at 09:11 UTC.
Financials & Fundamentals (XERS)
| Total Revenue | $314.85M |
|---|---|
| Revenue Growth (YoY) | +38.30% |
| Gross Margin | +85.89% |
| Operating Margin | +9.52% |
| Profit Margin | +3.81% |
| Debt / Equity | 1,987.19 |
| Current Ratio | 2.12 |
| Total Cash | $111.75M |
| Total Debt | $258.55M |
| Free Cash Flow | $42.21M |
Source: Nexqual, June 10, 2026 at 09:11 UTC.
Financial Health Score (XERS)
Nexqual rates Xeris Biopharma Holdings, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 09:11 UTC.
| Growth | Strong — Revenue +44% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 86%, operating 10% |
| Balance Sheet | Weak — $112M cash vs $259M debt |
| Cash Flow | Solid — FCF $42M, 14% margin |
| Efficiency | Mixed — No data |
Ownership (XERS)
| Insider Ownership | +3.37% |
|---|---|
| Institutional Ownership | +62.29% |
| Shares Outstanding | 172.64M |
| Float | 163.74M |
| Short % of Float | +7.50% |
Source: Nexqual, June 10, 2026 at 09:11 UTC.
Leadership (XERS)
Xeris Biopharma Holdings, Inc. is led by John P. Shannon (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 09:11 UTC.
| CEO & Director | John P. Shannon (age 63) |
|---|---|
| President & COO | Kevin McCulloch (age 61) |
| Chief Financial Officer | Steven M. Pieper (age 48) |
| Senior Vice President of Investor Relations & Corporate Communications | Allison Wey |
| Senior Vice President of Human Resources | Kendal Korte |
Major Backers & Investors (XERS)
Notable institutional backers of Xeris Biopharma Holdings, Inc. include Shaw D.E. & Co., Inc., Qube Research & Technologies Ltd, Rosalind Advisors, Inc., according to Nexqual as of June 10, 2026 at 09:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shaw D.E. & Co., Inc. | 4.51% |
| Qube Research & Technologies Ltd | 2.38% |
| Rosalind Advisors, Inc. | 1.87% |
| Morgan Stanley | 1.49% |
| Fidelity | 1.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.4% |
| Vanguard Group | 9.96% |
| State Street | 3.31% |
| Geode Capital | 2.49% |
| Nuveen | 1.69% |
Source: Nexqual, June 10, 2026 at 09:11 UTC.
From Xeris Biopharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Included in the total patents, we have 69 granted patents globally related to our platform technologies, and 5 patents granted and in force in the United States and listed in the United States Food and Drug Administration ("FDA") Orange Book covering proprietary formulations of levoketoconazole (the active pharmaceutical ingredient in Recorlev) and the uses of such formulations in treating certain endocrine-related diseases and syndromes.
- We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
- We believe this therapy represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration. • Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia.
- The estimated total addressable market for this therapy is 3-5 million patients or more in the United States which we estimate is a $1.0 to $3.0 billion peak net sales opportunity. • Partnerships: We are pursuing formulation and development partnerships to apply our XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies' proprietary drugs and biologics.
Partnerships
- We have entered into a non-exclusive supply agreement with Bachem.
- We have entered into a non-exclusive supply agreement with Pyramid.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | USD 3.99 | ▲ 1.53% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
| ARDX | Ardelyx, Inc. | USD 5.6 | ▲ 0.72% |
| MREO | Mereo BioPharma Group plc | USD 0.31 | ▼ 2.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:11 UTC. This page is informational and not investment advice.